ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics SA (NYSE:ADCT) has received a notice from the New York Stock Exchange (NYSE) for non-compliance with the continued listing minimum price criteria. The company failed to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.
November 07, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ADC Therapeutics has been notified by NYSE for non-compliance with the minimum price criteria. This could potentially lead to delisting if not rectified.
The NYSE notice indicates that ADC Therapeutics has not been able to maintain the minimum required average closing share price of $1.00 over a 30-day trading period. This non-compliance with NYSE listing standards could potentially lead to the company's delisting if not rectified, which would negatively impact the stock's liquidity and potentially its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100